|
Basic Characteristics of Mutations
|
|
Mutation Site
|
T1674C |
|
Mutation Site Sentence
|
Table 3. Results of HBV DNA genome analysis on HBV strain isolated during hepatitis B reactivation in a person with HIV after changing antiretroviral therapy regimen to cabotegravir/rilpivirine*. |
|
Mutation Level
|
Nucleotide level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
PreC;C |
|
Standardized Encoding Gene
|
C
|
|
Genotype/Subtype
|
A2 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HBV-HIV Coinfection
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
- |
|
Location
|
Japan |
|
Literature Information
|
|
PMID
|
39043430
|
|
Title
|
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody
|
|
Author
|
Adachi E,Sedohara A,Arizono K,Takahashi K,Otani A,Kanno Y,Saito M,Koga M,Yotsuyanagi H
|
|
Journal
|
Emerging infectious diseases
|
|
Journal Info
|
2024 Aug;30(8):1668-1671
|
|
Abstract
|
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.
|
|
Sequence Data
|
-
|